BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 688276)

  • 1. Estramustine phosphate in the treatment of advanced malignant melanoma.
    Lopez R; Karakousis CP; Didolkar MS; Holyoke ED
    Cancer Treat Rep; 1978 Sep; 62(9):1329-32. PubMed ID: 688276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral estramustine phosphate (Estracyt): a broad phase II study.
    Halpern J; Catane R
    J Med; 1984; 15(1):35-43. PubMed ID: 6593404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
    Mittelman A; Catane R; Murphy GP
    Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers].
    Wada T; Morikawa E; Houjou T; Kadota K; Mori N; Matsunami N; Watatani M; Yasutomi M
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1901-4. PubMed ID: 2393306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
    Toulouse J; Jung JL; Bittard M
    J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
    Trans Am Assoc Genitourin Surg; 1978; 70():69-71. PubMed ID: 753026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
    Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
    Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
    Lancina Martín JA; Chantada Abal V; Lamas Meilan AC; González Martín M
    Actas Urol Esp; 1984; 8(5):399-402. PubMed ID: 6524487
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
    Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
    Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of estramustine phosphate (Estracyt) in patients with metastatic melanoma.
    Jönsson PE; Ingvar C; Fernö M; Hafström L; Rudenstam CM
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):413-5. PubMed ID: 3383944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estracyt therapy in advanced prostate cancer: current status and personal results].
    Nagel R; Leistenschneider W
    Urologe A; 1983 May; 22(3):162-6. PubMed ID: 6683899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of advanced estrogen-resistant cancer of the prostate with estramustine phosphate. A phase-2 study].
    Trykker HU
    Ugeskr Laeger; 1985 Oct; 147(42):3310-2. PubMed ID: 4082315
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
    Keren-Rosenberg S; Muggia FM
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S26-9. PubMed ID: 9071337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor and binding site for estramustine in metastatic malignant melanoma.
    Fernö M; Borg A; Ingvar C; Jönsson PE
    Anticancer Res; 1987; 7(4B):741-3. PubMed ID: 3314674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
    Karakousis CP; Emrich LJ
    J Surg Oncol; 1987 Dec; 36(4):235-8. PubMed ID: 3695527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.